Journal Club - February 10, 2022
LAAOS-III Trial
Cathevine Yang presented the LAAOS-III Trial which was a multicenter, randomized trial of patients with atrial fibrillation, a CHA2DS2-VASc score of at least 2 and who were scheduled to undergo cardiac surgery for another indication. The participants were randomly assigned to undergo or not undergo occlusion of the left atrial appendage during surgery. The primary outcome was the occurrence of ischemic stroke or systemic embolism. The trial was published in NEJM in June and was presented at ACC in May.